Emerging Combination Injectable Therapy A New Era in Diabetes Care

Slides:



Advertisements
Similar presentations
……+(4n-3) = n(2n-1) P 1 = 1(2(1)-1)=1 check.
Advertisements

What's New in Basal Insulin for Diabetes
Copyright © 2015 by the American Osteopathic Association.
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Volume 384, Issue 9961, Pages (December 2014)
Copyright © 2015 by the American Osteopathic Association.
Expert Perspectives on New Treatment Options for Parkinson Disease Psychosis.
Short-, Intermediate-, Long-Acting Insulins
Updates and Perspectives in Diabetic Dyslipidemia
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Applying Data to Practice
New Patient-Friendly Options for Managing Insulin Dosing
SGLT2 Inhibitors and Their Clinical Impact:
Modern Strategies for Basal Insulin Use in T2D
Patient Case Discussions in T2D: What Intensification Plan Is Best?
Insulin Innovation.
Insulin/GLP-1 Agonist Combinations
Updates on Outcomes for Novel T2D Therapies
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus.
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Updates Abound.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Working as a Team for Improved Patient Outcomes in Type 2 Diabetes
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Innovative Insulin Combinations: A New strategy for the Person With T2DM.
How Effective Is Fixed-Dose Combination Therapy in T2D and Where Does It Fit?
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
Emerging Basal Insulins for Diabetes
GLP-1 Receptor Agonists: How Early Is Appropriate?
Managing Depression in Bipolar I Disorder
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
WHO Clinical Classification of PH Complex Cases in PH.
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Early and Intensive T2D Management:
Insulin/GLP-1 Agonist Combinations
Antihyperglycemic therapy in type 2 diabetes: general recommendations
Insulin Use in Primary Care: Practice Challenges
Insulin Innovation.
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).
Average patient profile in terms of (A) previous therapy drug class and (B) complexity of previous regimen. Average patient profile in terms of (A) previous.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Program. Basal Insulin in the Modern Era The CDE's Role in Improving Utilization and Outcomes.
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
CAD and HF Often Coexist
Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.
COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?
Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial
Patient Selection for Modern T2D Agents
Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.
Clinical Challenges and Updates in Managing Seizure Clusters
Assessing the Burden of Hyperkalemia
Assessing the Burden of Hyperkalemia
Range of mean changes from baseline in A1C in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists.
Range of mean changes from baseline in body weight in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor.
PAH Pathways: What Do the Data Tell Us?”
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).
Proportion of patients experiencing documented symptomatic hypoglycemia (blood glucose
Fixed-Ratio Combination Therapy in T2DM
Guideline approach to drug therapy in newly diagnosed type 2 diabetic patients not at target. Guideline approach to drug therapy in newly diagnosed type.
Emerging Basal Insulins for Diabetes
Fresh perspectives ON BASAL Insulins in diabetes care
In the Know.
Presentation transcript:

Emerging Combination Injectable Therapy A New Era in Diabetes Care

Program Notes and Goal

Historical Perspective Combination GLP-1 Agonist and Basal Insulin

Rationale and Proof of Concept GLP-1 Agonist + Basal Insulin

GLP-1 Agonist and Basal Insulin Combination A Meta-Analysis

Combined Single Administration of a GLP-1 Agonist and Basal Insulin

LixiLan. (glargine/lixisenatide LixiLan* (glargine/lixisenatide*) Fixed-Ratio Combination Safety and Efficacy

Facilitated Discussion Where Does It All Fit In?

Abbreviations

References

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.